IDH1 and glioblastoma: Additionally, the co‐deletion of 1p/19q and IDH1/2 mutations in patients with low‐grade glioma indicate a better clinical prognosis; however, the effect of these molecular events in glioblastoma (GBM) is unclear.10, 11